Determination of camostat and its metabolites in human plasma - Preservation of samples and quantification by a validated UHPLC-MS/MS method

被引:2
|
作者
Sorensen, Lambert K. [1 ]
Hasselstrom, Jorgen B. [1 ]
Gunst, Jesper D. [2 ]
Sogaard, Ole S. [2 ]
Kjolby, Mads [3 ,4 ,5 ]
机构
[1] Aarhus Univ, Dept Forens Med, Sect Forens Chem, Aarhus, Denmark
[2] Aarhus Univ Hosp, Dept Infect Dis, Aarhus, Denmark
[3] Aarhus Univ Hosp, Dept Clin Pharmacol, Aarhus, Denmark
[4] Aarhus Univ, DANDRITE, Dept Biomed, Aarhus, Denmark
[5] Aarhus Univ Hosp, Steno Diabet Ctr Aarhus, Aarhus, Denmark
关键词
Camostat; FOY-305; GBPA; FOY-251; GBA; COVID-19; Esterase inhibitors; LC-MS/MS; PROTEASE INHIBITOR; BILIARY-EXCRETION; RAT; TMPRSS2;
D O I
10.1016/j.clinbiochem.2021.07.007
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Camostat mesilate is a drug that is being repurposed for new applications such as that against COVID-19 and prostate cancer. This induces a need for the development of an analytical method for the quantification of camostat and its metabolites in plasma samples. Camostat is, however, very unstable in whole blood and plasma due to its two ester bonds. The molecule is readily hydrolysed by esterases to 4-(4-guanidinobenzoyloxy)phenylacetic acid (GBPA) and further to 4-guanidinobenzoic acid (GBA). For reliable quantification of camostat, a technique is required that can instantly inhibit esterases when blood samples are collected. Design and methods: An ultra-high-performance liquid chromatography-tandem mass spectrometry method (UHPLC-ESI-MS/MS) using stable isotopically labelled analogues as internal standards was developed and validated. Different esterase inhibitors were tested for their ability to stop the hydrolysis of camostat ester bonds. Results: Both diisopropylfluorophosphate (DFP) and paraoxon were discovered as efficient inhibitors of camostat metabolism at 10 mM concentrations. No significant changes in camostat and GBPA concentrations were observed in fluoride-citrate-DFP/paraoxon-preserved plasma after 24 h of storage at room temperature or 4 months of storage at-20 degrees C and-80 degrees C. The lower limits of quantification were 0.1 ng/mL for camostat and GBPA and 0.2 ng/mL for GBA. The mean true extraction recoveries were greater than 90%. The relative intralaboratory reproducibility standard deviations were at a maximum of 8% at concentrations of 1-800 ng/mL. The trueness expressed as the relative bias of the test results was within +/- 3% at concentrations of 1-800 ng/mL. Conclusions: A methodology was developed that preserves camostat and GBPA in plasma samples and provides accurate and sensitive quantification of camostat, GBPA and GBA by UHPLC-MS/MS.
引用
收藏
页码:56 / 62
页数:7
相关论文
共 50 条
  • [31] A novel, rapid and simple UHPLC-MS/MS method for quantification of warfarin in dried blood spots
    Qu, Wenhao
    Li, Xianglian
    Tian, Guidi
    Liu, Linsheng
    Miao, Liyan
    ANALYTICAL BIOCHEMISTRY, 2022, 647
  • [32] UHPLC-MS/MS method for simultaneous determination of tacrolimus, Cyclosporine A, sirolimus and Everolimus in human blood and clinical application
    Wang, Jiaqing
    Liu, Tongtong
    Zhang, Dongjie
    Li, Jian
    Ning, Xiao
    Zhao, Zhigang
    Mei, Shenghui
    CHINESE JOURNAL OF ANALYTICAL CHEMISTRY, 2025, 53 (01)
  • [33] SOLID-PHASE EXTRACTION COMBINED WITH UHPLC-MS/MS METHOD FOR DETERMINATION OF REMIFENTANIL IN HUMAN WHOLE BLOOD
    Lv, Jinling
    Li, Yanhua
    Jin, Hua
    Shi, Yao
    Xia, Qinghai
    Yang, Yaling
    ANALYTICAL LETTERS, 2012, 45 (10) : 1133 - 1142
  • [34] Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application
    Lindahl, Sofia
    Dyrkorn, Roar
    Spigset, Olav
    Hegstad, Solfrid
    THERAPEUTIC DRUG MONITORING, 2018, 40 (03) : 369 - 376
  • [35] A novel LC-MS/MS method for the simultaneous quantification of topiramate and its main metabolites in human plasma
    Milosheska, Daniela
    Roskar, Robert
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2017, 138 : 180 - 188
  • [36] An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma
    Montange, Damien
    Berard, Michel
    Demarchi, Martin
    Muret, Patrice
    Piedoux, Sarah
    Kantelip, Jean Pierre
    Royer, Bernard
    JOURNAL OF MASS SPECTROMETRY, 2010, 45 (06): : 670 - 677
  • [37] A UHPLC-MS/MS Method for Therapeutic Drug Monitoring of Aciclovir and Ganciclovir in Plasma and Dried Plasma Spots
    Pigliasco, Federica
    Cafaro, Alessia
    Simeoli, Raffaele
    Barco, Sebastiano
    Magnasco, Alberto
    Faraci, Maura
    Tripodi, Gino
    Goffredo, Bianca Maria
    Cangemi, Giuliana
    BIOMEDICINES, 2021, 9 (10)
  • [38] Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS
    Wiesena, Martin H. J.
    Blaich, Cornelia
    Streichert, Thomas
    Michels, Guido
    Mueller, Carsten
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2017, 55 (09) : 1349 - 1359
  • [39] Fast UHPLC-MS/MS for the Simultaneous Determination of Azithromycin, Erythromycin, Fluoxetine and Sotalol in Surface Water Samples
    Azzi, Mira
    Ravier, Sylvain
    Elkak, Assem
    Coulomb, Bruno
    Boudenne, Jean-Luc
    APPLIED SCIENCES-BASEL, 2021, 11 (18):
  • [40] A UHPLC-MS/MS bioanalytical assay for the determination of BMS-911543, a JAK2 inhibitor, in human plasma
    Liu, Jane
    Yuan, Long
    Liu, Guowen
    Shen, Jim X.
    Aubry, Anne-Francoise
    Arnold, Mark E.
    Ji, Qin C.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2015, 991 : 85 - 91